Authors : Rubica Elangovan; Lubna Fathima; M. S. Philomin Elgiva; Sindhu R.; Prabu D.; Rajmohan M.; Dinesh Dhamodhar

Volume/Issue : Volume 10 - 2025, Issue 11 - November

Google Scholar : https://tinyurl.com/ajuhh4hh

Scribd : https://tinyurl.com/y2tbkxjr

DOI : https://doi.org/10.38124/ijisrt/25nov649

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : Background: Cancer remains one of the top causes of death worldwide and, consequently, sparks the interest in the pursuit of safer and more effective therapeutic approaches. In recent decades, scientific interest has shifted to natural compounds for their potential therapeutic applications. Gallic acid (GA) is a polyphenolic compound derived from various fruits, herbs, and other plant-based sources that has emerged as a promising candidate based on its antioxidant and anticancer properties. This review intended to summarize the state of recent findings from 2010 to 2024 on anticancer effects, focusing on the mode of action of gallic acid, synergism with chemotherapeutic agents, and nanotechnology development in its delivery systems. Methods: A literature search of PubMed, ScienceDirect, and Google Scholar was made for relevant studies. Experimental and preclinical studies dealing with the role of gallic acid in different types of cancers were included. Results: The articles reviewed clearly show that gallic acid exerts its potent anticancer efficacy through a wide variety of mechanisms. It inhibits cancer cell proliferation, induces apoptosis, reduces inflammation, and suppresses metastasis of tumours. At the mechanistic level, GA adjusts some critical signalling pathways related to the survival and progression of cancer cells, particularly PI3K/Akt and MAPK. Combination of GA with other chemotherapeutic drugs increases the efficacy of treatment, whereas nanoparticle formulations improve its bioavailability and targeted delivery. Conclusion: This scoping analysis states that gallic acid is one of the promising natural anticancer agents that has considerable preclinical evidence to support its therapeutic benefits. However, more human clinical trials must be conducted to confirm its safety, dosage parameters, and clinical efficacy in order to be recommended for complementary or standalone therapies.

Keywords : Gallic Acid, Cancer, Apoptosis, Oxidative Stress, Nanoparticles, Chemotherapy.

References :

1. Keyvani- Ghamsari S, Rahimi M, Khorsandi K. An update on the potential mechanism of gallic acid as an antibacterial and anticancer agent. Food Sci Nutr. 2023;11(10):5856–72.
2. Ashrafizadeh M, Zarrabi A, Mirzaei S, Hashemi F, Samarghandian S, Zabolian A, et al. Gallic acid for cancer therapy: Molecular mechanisms and boosting efficacy by nanoscopical delivery. Food Chem Toxicol. 2021;157:112576.
3. Jiang Y, Jin PE, Zheng Y, Huang LF. Gallic acid: A potential anti-cancer drug. Chin J Integr Med. 2022;28(7):661–71.
4. Sharma V, et al. Synergistic effect of gallic acid with chemotherapeutic agents: A molecular insight. Int J Mol Sci. 2022;23(9):4950.
5. Martínez-Senra T, Maciołek U, Losada-Barreiro S, Bravo-Díaz C. Synergistic effects of binary mixtures of δ-tocopherol and gallic acid derivatives on peroxidation of soybean oil-in-water emulsions. LWT. 2024;213:117014.
6. Li Z, et al. Gallic acid triggers apoptosis via p53 pathway in A375 melanoma cells. Mol Med Rep. 2013;8(1):243–9.
7. Dhingra D, et al. ROS-mediated cytotoxic effects of gallic acid in leukemia cell models. Biomed Pharmacother. 2022;146:112602.
8. Subramanian AP, Jaganathan SK, Mandal M, Supriyanto E, Muhamad II. Gallic acid induced apoptotic events in HCT-15 colon cancer cells. World J Gastroenterol. 2016;22(15):3952–63.
9. Ma Y, et al. Co-administration of gallic acid enhances paclitaxel-induced apoptosis in breast cancer. J Cell Biochem. 2020;121(3):2063–74.
10. Bai J, Zhang Y, Tang C, Hou Y, Ai X, Chen X, et al. Gallic acid: Pharmacological activities and molecular mechanisms involved in inflammation-related diseases. Biomed Pharmacother. 2021;133:110985.
11. Jezierzański M, Nafalska N, Stopyra M, Furgoł T, Miciak M, Kabut J, et al. Temozolomide (TMZ) in the treatment of glioblastoma multiforme—a literature review and clinical outcomes. Curr Oncol. 2024;31(7):3994–4002.
12. Yang JT, Lee IN, Chen CH, Lu FJ, Chung CY, Lee MH, et al. Gallic acid enhances the anti-cancer effect of temozolomide in human glioma cell line via inhibition of Akt and p38-MAPK pathway. Processes. 2022;10(3):448.
13. Pang JHS, et al. Gallic acid suppresses MMP-1 transcription through AP-1/ETS-1 in nasopharyngeal carcinoma. Int J Mol Sci. 2017;18(7):1354.
14. Zhao Y, Li D, Zhu Z, Sun Y. Improved neuroprotective effects of gallic acid-loaded chitosan nanoparticles against ischemic stroke. Rejuvenation Res. 2020;23(4):284–92.
15. Yafout M, Ousaid A, Khayati Y, El Otmani IS. Gold nanoparticles as a drug delivery system for standard chemotherapeutics: A new lead for targeted pharmacological cancer treatments. Sci Afr. 2021;11:e00685.
16. Bhuia MS, Rahaman MM, Islam T, Bappi MH, Sikder MI, Hossain KN, et al. Neurobiological effects of gallic acid: Current perspectives. Chin Med. 2023;18(1):27.
17. Liang J, Lu T, Shan T, Liang H, Wang W, Song Z, et al. Gallic acid potentiates the anticancer efficacy of cisplatin in ovarian cancer cells through modulation of the PI3K/AKT/mTOR and CXCL12/CXCR4 signalling pathways. Front Oncol. 2025;15:1653538.
18. Kang DY, Bae SW, Jang KJ. Natural bioactive gallic acid shows potential     anticancer effects by inhibiting the proliferation and invasiveness behavior in human embryonic carcinoma cells. Molecular Medicine Reports [Internet]. 2025;31:1–14. Available from: https://doi.org/10.3892/mmr.2025.13516
19. Subramanian AP, John AA, Vellayappan MV, Balaji A, Jaganathan SK, Supriyanto E,               et al. Gallic acid: Prospects and molecular mechanisms of its anticancer activity. RSC Adv. 2015;5(45):35608–21.
20. Meng R, Zhang Z. Gallic acid inhibits the proliferation and migration of ovarian cancer cells via inhibition of the PI3K‐AKT pathway and promoting M1‐Like macrophage polarization. Analytical Cellular Pathology [Internet]. 2025;2025:3880719. Available from: https://doi.org/10.1155/ancp/3880719